Ghent University Academic Bibliography

Advanced

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial.

L BIGANZOLI, T CUFER, P BRUNING, R COLEMAN, Luc Duchateau UGent, AH CALVERT, T GAMUCCI, C TWELVES, P FARGEOT, R EPELBAUM, et al. (2002) JOURNAL OF CLINICAL ONCOLOGY. 20(14). p.3114-3121
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
journal title
JOURNAL OF CLINICAL ONCOLOGY
J. Clin. Oncol.
volume
20
issue
14
pages
3114-3121 pages
Web of Science type
Article
Web of Science id
000176920000011
JCR category
ONCOLOGY
JCR impact factor
9.868 (2002)
JCR rank
4/112 (2002)
JCR quartile
1 (2002)
ISSN
0732-183X
language
English
UGent publication?
yes
classification
A1
id
149290
handle
http://hdl.handle.net/1854/LU-149290
date created
2004-01-14 13:38:00
date last changed
2016-12-19 15:37:50
@article{149290,
  author       = {BIGANZOLI, L and CUFER, T and BRUNING, P and COLEMAN, R and Duchateau, Luc and CALVERT, AH and GAMUCCI, T and TWELVES, C and FARGEOT, P and EPELBAUM, R and LOHRISCH, C and PICCART, MJ},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  language     = {eng},
  number       = {14},
  pages        = {3114--3121},
  title        = {Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial.},
  volume       = {20},
  year         = {2002},
}

Chicago
BIGANZOLI, L, T CUFER, P BRUNING, R COLEMAN, Luc Duchateau, AH CALVERT, T GAMUCCI, et al. 2002. “Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.” Journal of Clinical Oncology 20 (14): 3114–3121.
APA
BIGANZOLI, L., CUFER, T., BRUNING, P., COLEMAN, R., Duchateau, L., CALVERT, A., GAMUCCI, T., et al. (2002). Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. JOURNAL OF CLINICAL ONCOLOGY, 20(14), 3114–3121.
Vancouver
1.
BIGANZOLI L, CUFER T, BRUNING P, COLEMAN R, Duchateau L, CALVERT A, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. JOURNAL OF CLINICAL ONCOLOGY. 2002;20(14):3114–21.
MLA
BIGANZOLI, L, T CUFER, P BRUNING, et al. “Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.” JOURNAL OF CLINICAL ONCOLOGY 20.14 (2002): 3114–3121. Print.